Heterologous ChAdOx1/BNT162b2 vaccination induces stronger immune response than homologous ChAdOx1 vaccination: The pragmatic, multi-center, three-arm, partially randomized HEVACC trial

BACKGROUND: Several COVID-19 vaccines have been approved. The mRNA vaccine from Pfizer/BioNTech (Comirnaty, BNT162b2; BNT) and the vector vaccine from AstraZeneca (Vaxzevria, ChAdOx1; AZ) have been widely used. mRNA vaccines induce high antibody and T cell responses, also to SARS-CoV-2 variants, but...

Descripción completa

Detalles Bibliográficos
Autores principales: Bánki, Zoltán, Mateus, Jose, Rössler, Annika, Schäfer, Helena, Bante, David, Riepler, Lydia, Grifoni, Alba, Sette, Alessandro, Simon, Viviana, Falkensammer, Barbara, Ulmer, Hanno, Neurauter, Bianca, Borena, Wegene, Krammer, Florian, von Laer, Dorothee, Weiskopf, Daniela, Kimpel, Janine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126042/
https://www.ncbi.nlm.nih.gov/pubmed/35617826
http://dx.doi.org/10.1016/j.ebiom.2022.104073

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9126042/
https://www.ncbi.nlm.nih.gov/pubmed/35617826
http://dx.doi.org/10.1016/j.ebiom.2022.104073

Ejemplares similares